Recently, Shanghai Stansai Biotechnology Co., Ltd. ("Sdansai Bio") announced the completion of the B round of financing, financing amount of 180 million yuan, Gao Tejia investment led. Since its inception in 2009, Standan Bio has been involved in the research and application of cutting-edge CAR-T technology, gene editing technology and stem cell technology. The CD19 CAR-T developed by Stansai Biotechnology for the treatment of advanced acute lymphoblastic leukemia has conducted 39 clinical trials in the Department of Hematology of more than 10 top three hospitals nationwide since 2014, with a complete remission rate of 84.6%. The MRD has a negative rate of 80%, reaching the international leading level. Moreover, Stanisel's CAR-T treatment of lymphoma has also been successful, and clinical trials for solid tumors such as breast cancer and pancreatic cancer have been initiated in several hospitals.
Our PP Resin is used to manufacture various port with different models, such as Single Port, Double Port ,Small Port etc . We have a excellent supply-chain in our product materials. If you have any specific requirements, let us know, we will do our best to meet your requirements.In our website,we provide the images and basic parameters for each products. We are a professional chinese manufacturer of medical packaging and look forward to your inquiries! Pp Resin For Port,Polypropylene Pp Copolymer Resin,Pp Granules Pp Resin,Pp Pellets Pp Resin Suzhou CRH New Material Technology Co.,Ltd. , https://www.crh-health.com